SPOTLIGHT: Wyeth may cut 10% of jobs

Welcome Wyeth to the layoff parade. The drug maker is plotting cutbacks, including job cuts that could amount to 10 percent of its 50,000-person workforce. Report

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.